Affordable access Target governo ments and public health programs seeking low-cost cervical cancer screening solutions; Aindra's CervAstra offers a quick, walk-in screening at primary health centers, aligning with initiatives to expand screening coverage in resource-constrained settings.

AI powered screening Leverage Astra AI platform for scalable detection of cervical cancer and other critical illnesses; position as a software-enabled hardware solution that can be deployed across clinics with minimal infrastructure upgrades.

Strategic partnerships Explore collaboration opportunities with IITs, medical universities, and government labs to co-develop and validate AI screening tools, accelerating product adoption and credibility in healthcare systems.

Early stage funding Capitalize on recent small-scale funding rounds to attract grant-based support and seed investments; highlight traction from 304K raised to demonstrate validation and potential for larger rounds with impact-oriented investors.

Healthcare digitization Position CervAstra as part of a broader digital pathology and point-of-care ecosystem; emphasize computational pathology benefits, enabling scalable screening programs with rapid reporting at primary centers.